VečerIndependent🔒Center3 hr. agoThe article discusses the decision by the Slovenian Health Insurance Institute (ZZZS) to deny funding for the treatment of a boy named Tea in the United States. The decision was made by a medical council of pediatricians who concluded that there was no expectation of recovery, improvement, or prevention of deterioration in the child’s health. They noted that while the drug Duvezat (givinostat) is available in Slovenia and could potentially slow disease progression, the clinical trial results for Elevidys, a gene therapy, were inconclusive. The European Medicines Agency (EMA) did not approve Elevidys for marketing in the EU due to lack of evidence of effectiveness, and two children involved in trials died from liver failure. The council expressed concerns about the potential risks of gene therapy using viral vectors, which have not been proven effective, and warned that this could hinder future treatments with similar vectors. The family requested external experts to review the case but received only partial responses.
Bias read (Center): The article presents a balanced assessment of the medical council's decision based on scientific evidence and regulatory approvals. It does not take a clear ideological stance but rather reports on the technical and ethical considerations surrounding the treatment approval process. While the issue涉及
ZZZS refused to fund the treatment of the boy Tea in the USThe Slovenian Health Insurance Institute (ZZZS) rejected funding for the treatment of a boy named Tea with Duchenne muscular dystrophy using the medication Elevidys in the United States. The decision was based on the opinion of a panel of doctors who stated that there is no expectation of cure, improvement, or prevention of deterioration in the child’s health. The panel noted that while the US-based treatment might offer some benefits, it has not been proven effective by the European Medicines Agency (EMA). They also raised concerns about potential risks, including fatalities in clinical trials and possible interference with future treatments using similar viral vectors. The decision sparked controversy, leading to calls for external expert input from the US and Canada, though responses were not fully received.
Bias read (Center): While the issue involves a controversial medical treatment and public funding decisions, the article presents both sides of the debate, criticism of the treatment's efficacy and concerns over potential harm, without overtly favoring either side. The framing remains balanced between the arguments of ZZ
ZZZS refused to fund the treatment of the boy Tea in the USThe Slovenian Health Insurance Institute (ZZZS) has denied funding for the treatment of boy Tea in the United States. The decision was made on July 24th, and explanations were provided due to an ongoing donor campaign for Tea. The Council for Advanced Treatments at the Pediatric Clinic of the University Clinical Center Ljubljana concluded that there are still unexplored treatment options for Duchenne muscular dystrophy in Slovenia, including the medication Duvezat (givinostat), which was approved by the European Medicines Agency (EMA) in June 2025 and is available in Slovenia. However, the council analyzed clinical trial results for Elevidys and found that the third-phase EMBARK study did not meet its primary goal, as there was no statistically significant difference in motor function assessments between children receiving Elevidys and those receiving a placebo. The council noted that EMA did not grant marketing authorization for Elevidys in the EU due to lack of evidence of efficacy, and two children involved in trials died from liver failure. They also expressed concerns that unproven gene therapy could hinder future effective treatments using the same viral vector. The council's
Bias read (Center): The article presents a balanced analysis of the medical and ethical considerations surrounding the potential treatment for Tea. It includes both the arguments against funding Elevidys based on clinical trial outcomes and the concerns raised by the council regarding the risks and limitations of the疗法
The ZZZS explained why they won't pay for Tea's treatmentThe ZZZS (Health Insurance Fund of Slovenia) denied funding treatment for a boy named Tea who has Duchenne muscular dystrophy using the medication Elevidys in the US. The decision was made on July 24th and was explained due to an ongoing donation campaign for Tea. A committee of pediatric specialists reviewed clinical trial results and concluded that the phase III EMBARK study did not show statistically significant improvements in motor function or other indicators. They noted that the European Medicines Agency (EMA) had not approved Elevidys for sale in the EU by July 2025 due to lack of evidence of effectiveness. Two children involved in trials with this medication died from liver failure. The committee also warned that genetic therapy using this drug could hinder future effective gene therapies with the same viral vector. They emphasized that such treatment is not available anywhere in the EU, including Italy, where rare disease care guidelines do not cover such treatments abroad. A legal representative requested the inclusion of foreign experts in the review process.
Bias read (Center): The article presents a balanced analysis of the medical and regulatory considerations surrounding the approval of Elevidys for treating Duchenne muscular dystrophy. It includes both the ZZZS’s decision and the expert committee’s findings, without overtly favoring either side. While there is some nuh
ZZZS refused to fund the treatment of the boy Tea in the United States, explained the reasonsThe ZZZS (Slovenian Health Insurance Institute) rejected funding for the treatment of a boy named Tea in the United States with the drug Elevidys, stating that there was no evidence of effectiveness. The decision was made on July 24th, and the reasons were provided due to an ongoing donation campaign for Tea. The Pediatric Advanced Therapy Council at the University Clinical Center Ljubljana noted that treatment options for Duchenne muscular dystrophy in Slovenia are not exhausted and suggested using the drug Duvyzat (Givinostat), which became available in Slovenia in June 2025. They emphasized that clinical trials for Elevidys did not show statistically significant improvements, and the European Medicines Agency (EMA) had not approved the drug for sale in the EU due to lack of proven efficacy. Concerns were raised about potential harm to future gene therapies if Elevidys' vector is used without proven results.
Bias read (Center): While the issue involves healthcare policy and public funding decisions, which are politically sensitive, the article presents both sides of the debate, ZZZS’s rejection based on lack of evidence and the alternative treatment options proposed by the council. There is no clear ideological leaning in报道
ZZZS won't pay for Tea's treatment in the U.S.The Slovenian Health Insurance Institute (ZZZS) has decided not to cover the treatment of a boy named Tea for Duchenne muscular dystrophy in the United States. The decision was based on a report by the Council for Advanced Treatments at the Pediatric Clinic of the University Clinical Center Ljubljana, which concluded that the treatment would not lead to recovery, improvement, or prevention of health decline. The council noted that effective treatments for Duchenne muscular dystrophy in Slovenia are not exhausted and that the drug duvyzat (givinostat), approved by the European Medicines Agency (EMA) in June 2025, could potentially slow disease progression. However, the council analyzed clinical trial results for the drug elevidys and found no statistically significant difference between those who received the drug and those who received a placebo after 52 weeks. Additionally, the EMA did not approve elevidys for marketing in the EU due to insufficient evidence of effectiveness, and two children involved in the trials died from liver failure. The council expressed concerns about the potential impact of unproven gene therapy using viral vectors on future treatments.
Bias read (Center): The article presents a balanced view of the situation, including both the reasons provided by the ZZZS and the concerns raised by the medical council. It does not favor one side over the other but provides detailed information on the medical evaluations and decisions made.
DeloIndependent🔒Center5 hr. agoThe Slovenian Health Insurance Institute (ZZZS) rejected funding for the treatment of a boy named Tea with Duchenne muscular dystrophy using the medication Elevidys in the United States. The decision was based on the opinion of a panel of doctors who stated that there is no expectation of cure, improvement, or prevention of deterioration in the child’s health. The panel noted that while the US-based treatment might offer some benefits, it has not been proven effective by the European Medicines Agency (EMA). They also highlighted that two children involved in clinical trials for this treatment died due to liver failure. In contrast, the panel suggested that the drug Duyvazat (Givinostat), which is available in Slovenia, could potentially slow disease progression. The ZZZS decision was made on July 24th, and the organization provided explanations due to an ongoing donation campaign for Tea. Critics argue that the decision overlooks potential benefits and raises concerns about limiting future access to effective gene therapy.
Bias read (Center): While the issue involves healthcare policy and public funding decisions, the article presents both sides of the debate, critics of the decision and those supporting it based on medical evidence. The framing remains balanced, presenting the arguments of the ZZZS and the opposing expert opinions. There
Slovenia
